Oral weight loss therapy, Semaglutide reduces patient weight by 15%

Novo Nordisk has released the main results of OASIS 1, a phase 3a trial in the global OASIS program. OASIS 1 is a 68 week efficacy and safety trial that compared 667 obese or overweight adults with one or more syndromes. One group takes 50 milligrams of Semaglutide orally once a day. The other group is a placebo for weight management. Both treatment groups were combined with lifestyle interventions. This experiment demonstrates that oral administration of Semaglutide 50 mg can significantly reduce weight compared to placebo at week 6, thereby achieving its primary endpoint.

When evaluating the therapeutic effect of treatment 1 with an average baseline weight of 105.4 kg for all individuals, patients receiving oral Semaglutide 50mg lost 17.4% of their weight after 68 weeks, while those receiving placebo lost 1.8%, which was statistically significant. In addition, 89.2% of patients who took Semaglutide 50 mg orally lost 5% or more of their weight after 68 weeks, while the proportion using placebo was 24.5%.